International Journal of Scientific Research and Engineering Development-– Volume 4 Issue 5, Sep- Oct 2021

Available at www.ijsred.com

RESEARCH ARTICLE OPEN ACCESS

Review on Growth Hormone and Ageing

Pitchayanant Laemad*

*Ekamai International School, KlongtanNhuea, Wattana, Bangkok, Thailand 10110

Email: Laemadpit@gmail.com

----------**********----------

Abstract:

The role of mammalian growth hormone (GH) is intensively examined in clinical, epidemiological and investigational studies. The decrease in GH levels due to age is diversely considered symptoms of neuroendocrine ageing, cause of changing physique and other adverse ageing indicators, or a function for the natural defence against cancer and other chronic illnesses. The lack of growth hormone signals due to abnormalities that have affected earlier progress, GH production, or GH receptors results in an astonishing increase in lab mouse lifespan. The extension of these animals' lifespan and survival curves implies that ageing is reduced or decreased in the absence of GH. The associated human endocrine disorders do not have a constant lifetime but offer outstanding age protection. In addition, survival at ancient age was associated with a decrease in somatotropic signals for men and women. Both humans and mice correlate GH levels with greater risk for illness and lower life expectancy with an ageing stimulation in the astounding range. Thus, there has been much attention to GH's widely publicised possibility as an anti-ageing agent. The results have proved misleading since they consisted of only a few verified advantages and numerous severe side effects. Nevertheless, it still has to be investigated the efficacy of GH in treating other chronic diseases.

Keywords **—Human Growth hormone, Lifespan, Aging, Growth Hormone deficient, somatotropic signals**

----------**********----------

I. INTRODUCTION

Various changes are linked to the ageing of the endocrine system (1). These various changes are strongly indicated, ready for examination and publication (2). The biological activity of such changes is nonetheless hard to evaluate. Age decline in circulation of a specific hormone, androstenolone, estradiol-17 beta, testosterone, or growth hormone (GH),is, therefore, a marker of ageing as one of the likely reasons or protection against alterations and dangers in the aged body (3, 4). The growth hormone (GH) functions significantly affect the mammalian ageing process, supported by essential data (1). However, the GH role of various species differs quantitatively. This review presents a critique of putative connections between GH and ageing, focusing on current data. In addition, the connections between GH-dependent and age-related illnesses, the health and life expectancy of mammalian species and humans.

II. THE EFFECTS OF GH SIGNALLING AFFECTING AGEING IN MICE MODELS

Over half a century ago, Silberberg had reported a study on age-related osteoarthritis found that mice with hereditary dwarfism could live longer (5). Dwarf mice with deficiency of GH, prolactin, and thyroid-stimulating hormone (TSH) were found to have prolonged life spans (6, 7). The function loss in Pituitary 1 (Pit-1) or Prophet of Pit 1 (Prop1) is due to mutants with altered endocrine function, leading to abnormalities in the distinction of matching cell lineages in the previous hypophysis

 ©IJSRED:All Rights are Reserved

(8-10). The longer lifetime of Ames dwarf (Prop1df) mice was initially primarily related to GH deficienciesand essential data now supports this hypothesis (11-13). It was found that GH deficient mice generated by a mutation of the GH-released hormone (GHRH) receptor gene are similarly long-lived, but lifespan growth has been moderate and dietary-dependent (14). GH resistance is associated improved longevity in men and women and not restricted to animals of a comprehensive genetic history (1). Also, Stout and collegues reported that hite adipose tissue (WAT) could play a critical roles in age-related disease due to the thedysfucntion of WAT and senescent cells accumulation were related with GH activity (15). Further studies on the GH activity induced senescent cells accumulation in WAT has been perform by several groups of researcher in mice model. It has been reported that obesity, insulin sensitivity, and GH have antagonistic impacts on IGF bioactivity via an insulin-mediated suppression of IGF-binding protein-3 (IGFBP-3) (16). A different study studied the metabolic benefits of stimulating endogenous GH secretion by a synthetic GHSR (GHSR agonist) called hexarelin. Male MC4RKO mice were pair-fed and given hexarelin continuously (17). The hexarelin treatment improved insulin sensitivity without affecting insulin or IGF-1 levels in obese MC4RKO mice (17). This provides evidence that increasing pulsatile GH secretion in the pituitary gland through activation of the GHSR in the pituitary gland can aid in the management of obesity (17).

III. INTERACTING PROCESSES DIMINISHED GH, DELAYED AGEING, AND PROLONGED LIFE

Most tissues possess receptors of GH, and GH affects development, numerous metabolism processes, and body composition in many paths. Therefore, it is not surprising that the research into mechanisms that connected the suppression of GH signal to delayed ageing and increased lifetime shows many of the physiological processes and characteristics involved (2, 18). Most of these processes involved reducing pathways promoting synthetic anabolic pathways such as IGF-1 and mTORC1and pro-inflammatory and anti-inflammatory cytokines including IL-1β, IL-6, and TNF-α (19-23). In addition, anti-inflammatory factors are suppressed while pro-inflammatory factors are enhanced; and several steps were undertaken to increase the utilisation of fats as an energy source (21, 24). Repressing GH signals can slow ageing progress and prolonged life and health by enhancing genome maintenance (25, 26).Recent studies demonstrated that Ames dwarf mouse's ovaries have an enhanced capacity for repairing DNA double-strand breaks (13, 24). Therefore, the GH resistant mice model could explain the molecular reasons for delayed ovarian ageing. Also, the number of senescent cells in mice was negatively correlated with the length of life span (15).

GH signals are interlinked with health and ageing, which generates a complex interactions with pleiotropic effects (27). Chronically low-grade inflammation is decreased due to alterations in the cytokine profile emitted by adipose tissue and decreases in oxidative stress and senescent cells (28). This leads to dramatically enhanced insulin sensitivity in combination with lower insulin levels, greater adiponectin levels, reduced mTORC1 signals, increased mTORC2 signals and the lack of supprimative impact of GH on the insulin signalling pathway (29-31). The necessity for insulin production is lessened because the low sensitivity to insulin helps maintain the low insulin level ascribed to the effect of lower GH and IGF-2 pancreatic beta cells on the development and function of insulin-producing signals (29). Complementary to decreased insulin levels, the positive effects of lowered IGF-1 and GH on neoplasms, combined with lower mTORC1 activity, might lead to a lower ageing rate of GH-associated mutations (1, 29-31). The demand for insulin production is reduced because the low sensitivity of insulin helps maintain the low insulin level, which can be linked to the effect on growth and function of lower GH and IGF-2 pancreatic beta cells, which produce insulin (32, 33). Therefore, decreased insulin levels, lowered in IGF-1 and GH combined with lower mTORC1 activity, may contribute to the lower ageing rate of GH related mutations.

 ©IJSRED: All Rights are Reserved

IV. HUMAN LONGEVITY IS ASSOCIATED WITH GROWTH HORMONE

The primary evidence that GH signals play an essential role in regulating human ageing was indirect and frequently contradictory. Numerous cases of a negative longevity-high, GH-dependent characteristic (25). There have, however, been reports of certain occurrences of more prominent people surviving longer. Serveral studies give further evidence of shorter people's more prolonged survival with a discovered link between GH, IGF-1, and its downstream targets of gene polymorphism, with outstanding lifespan (34, 35).

Investigations have shown that the interest in human ageing with the same genetic defect or dwarfism with distinct etiologies in small mice that lack GH and GHR has been significantly expanded (1). However, these investigations have produced unequivocal answers. A certain number of patients with isolated GH deficiency (GHD) were caused by hormone-related GH-release mutations, Prop1, lack of GH (Laron syndrome), and genetic modifications hypopituitarism has reached a certain age (36-38). Excess GH syndrome pre-maturation gigantism appears to connect with an extremely high chance of developing death, although studieswere evidence of that syndrome in particular (39, 40). The risks of diabetes, cardiovascular illnesses and acromegaly were similar to the incidences of chronological age and may be seen as a fast-ageing indication (41).

Recent research has revealed substantial additional evidence of GH's function in human ageing in the recent decade. The study discovered that the lifespan of FOXO3 alone and fasting blood insulin levels in humans and others are negatively connected (41-43). Low blood levels of IGF-1 were consistent with decreased GH signals in such people, but surprisingly, they were taller than males without this variation. The link between development and lifespan was explored by Tanisawa et al. in comparing the frequencies of rising height alleles for significant cohorts and control subjects (44). This innovative technology eliminates major confusing factors like diet and infant illnesses that might affect the height of adults. The results indicated that Japanese women had an opposite connection between high-growth alleles and extended longevity subjects (44).

Mutations that distort human GH signalling give excellent immunity from several age-related illnesses are also significantly shown. Initial discoveries of decreased risk of cancer were supported by evidence that members of the Laron dwarf significant cohort in Ecuador were nearly fully protected from cancer and diabetes in persons with a hereditary GH resistance (Laron dwarf syndrome)(23, 38, 45). These people were recently found to have significant increases of adiponectin and increased insulin sensitivity, despite increased body fat percentage, increased cognitive ability and physical features of the hippocampus in the brain, and other regions of the brain similar to younger relatives (46). Also, patients with isolated GHD are secure from atherosclerosis, despite poor serum profiling and common obesity (38, 47, 48).

V. DISPUTES ON THE SIGNIFICANCE OF GH IN AGEING

GH can undoubtedly have both pro-and anti-ageing effects at various periods in the history of life. Early-life stimulation, development and fertility are linked to the acceleration of the ageing process employing several interference-planning processes (49, 50). However, GH's effects on body composition, function and metabolism in later life can be protective. As well as the effect of GH on thermal and immune systems, the lipolytic effects of GH may also be beneficial in preventing and curing senior sarcopenia, particularly for individuals who are overweight or obese (49).

The most contentious and largely unsolved problem is the difference in mice and men between the consequences of GH deletion (or repression)(1). Growth hormonally deficient or resistant to GH mice are long-lived, and people with mutations producing equal endocrine abnormalities do not have any apparent life expectancy changes, and there has been at least a short-lived cohort of GH-deficient subjects (1). It is difficult to explain these significant variations in the connection between GH signs and lifespan. These variations represent the different features of quick-to-slow creatures. Rapid development, early sexual maturation, and a

 ©IJSRED: All Rights are Reserved

massive amount of offspring are often connected with shorter lifetime expectations in mice and other fast-paced animals (18, 25). However, people and other slow-paced creatures have contradicting qualities and are mostly long-lasting. The elimination of GH signals from mice encourages a lighter lifestyle that leads to slower somatic growth, slower puberty and reduced fertility (18, 31, 51). The effects on human development, maturation and fertility of the GH deficit and resistance in mice, are comparable but evidently, in a species with a slower lifetime and a lifetime much longer than anticipated from the adult body or basal metabolism, have no (or very little) influence on lifetime (51). Much further study is required to substantiate these hypotheses or disprove them. Note that in the late-life chronic diseases and the health of mice or men, the consequences of removing GH signals are generally comparable, and both species have less lifetime of pathological GH excess.

CONCLUSIONS

GH molecular actions have a significant influence on animal ageing processes and also affecting other mammalian species, including humans. However, there is much room for incoherence and controversy. The discrepancy between studies on lifespan in mice and humans is of particular interest among them. Pathological GH excess, however in both species, is related to comorbidities and decreased lifespan. Multiplied investigations of both species have found negative GH and adult body sizes (GH-dependent characteristic) with lifespan, although the mice are more apparent and persistent.

Somatotropic signalling related genes encourage growth, sexual maturity and fertility, which are the essential features of evolutionary fitness. Hence, their activity is evolutionarily chosen, even if they can have harmful consequences on the risk of disease and survival later in life. This notion certainly applies extensively to the genetic regulatory system of ageing and is well suited to the relatively unexpected results of either loss of function mutations or mutations of gene expression of the bulk of the powerful genes identified in different species of 'long life.'

A considerable quantity of study determines the function of somatotropic signals in managing aging, ageing-related illnesses and life in many parts of life history. It can be assumed that study on the function of GH in the ageing of various types leads to new results that have essential effects on personal and public health, the processes involved, and how these mechanisms interact with environmental issues.

REFERENCES

1. Aguiar-Oliveira MH, Bartke A. Growth hormone deficiency: health and longevity. Endocrine reviews. 2019;40(2):575-601.
2. Bartke A. Growth hormone and aging: updated review. The world journal of men's health. 2019;37(1):19-30.
3. Barrientos G, Llanos P, Basualto-Alarcón C, Estrada M. Androgen-regulated cardiac metabolism in aging men. Frontiers in Endocrinology. 2020;11:316.
4. Racoubian E, Aimagambetova G, Finan RR, Almawi WY. Age-dependent changes in anti-Müllerian hormone levels in Lebanese females: correlation with basal FSH and LH levels and LH/FSH ratio: a cross-sectional study. BMC Women's Health. 2020;20(1):1-6.
5. Silberberg R. Articular aging and osteoarthrosis in dwarf mice. Pathobiology. 1972;38(6):417-30.
6. Flurkey K, Papaconstantinou J, Miller RA, Harrison DE. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proceedings of the National Academy of Sciences. 2001;98(12):6736-41.
7. Bartke A, Brown-Borg H, Mattison J, Kinney B, Hauck S, Wright C. Prolonged longevity of hypopituitary dwarf mice. Experimental gerontology. 2001;36(1):21-8.
8. Cheung LYM, Camper SA. PROP1-dependent retinoic acid signaling regulates developmental pituitary morphogenesis and hormone expression. Endocrinology. 2020;161(2):bqaa002.
9. Zhang S, Cui Y, Ma X, Yong J, Yan L, Yang M, et al. Single-cell transcriptomics identifies divergent developmental lineage trajectories during human pituitary development. Nature communications. 2020;11(1):1-16.
10. Bulut FD, Dilek SÖ, Kotan D, Mengen E, Gürbüz F, Yüksel B. Mutations Within the Transcription Factor PROP1 in a Cohort of Turkish Patients with Combined Pituitary Hormone Deficiency. Journal of clinical research in pediatric endocrinology. 2020;12(3):261.
11. Mattison JA, Wright C, Bronson RT, Roth GS, Ingram DK, Bartke A. Studies of aging in Ames dwarf mice: effects of caloric restriction. Journal of the American Aging Association. 2000;23(1):9-16.
12. Masternak MM, Darcy J, Victoria B, Bartke A. Dwarf mice and aging. Progress in molecular biology and translational science. 2018;155:69-83.
13. Saccon TD, Rovani MT, Garcia DN, Mondadori RG, Cruz LAX, Barros CC, et al. Primordial follicle reserve, DNA damage and macrophage infiltration in the ovaries of the long-living Ames dwarf mice. Experimental gerontology. 2020;132:110851.
14. Santos-Carvalho HA, Aguiar-Oliveira MH, Salvatori R, Valença EHO, Andrade-Guimarães AL, Palanch-Repeke CE, et al. Vestibular function in severe GH deficiency due to an inactivating mutation in the GH-releasing hormone receptor gene. Endocrine. 2020;67(3):659-64.
15. Stout MB, Tchkonia T, Pirtskhalava T, Palmer AK, List EO, Berryman DE, et al. Growth hormone action predicts age-related white adipose tissue dysfunction and senescent cell burden in mice. Aging (Albany NY). 2014;6(7):575.
16. Dichtel LE, Bjerre M, Schorr M, Bredella MA, Gerweck AV, Russell BM, et al. The effect of growth hormone on bioactive IGF in overweight/obese women. Growth Hormone & IGF Research. 2018;40:20-7.

 ©IJSRED: All Rights are Reserved

17. Huang Z, Lu X, Huang L, Zhang C, Veldhuis JD, Cowley MA, et al. Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces the fat accumulation and improves the insulin sensitivity in obese mice. The FASEB Journal. 2021;35(1):e21269.
18. Gesing A, Wiesenborn D, Do A, Menon V, Schneider A, Victoria B, et al. A long-lived mouse lacking both growth hormone and growth hormone receptor: a new animal model for aging studies. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2017;72(8):1054-61.
19. Kim S-S, Lee C-K. Growth signaling and longevity in mouse models. BMB reports. 2019;52(1):70.
20. Sawa R, Nishida H, Yamamoto Y, Wake I, Kai N, Kikkawa U, et al. Growth hormone and Insulin-like growth factor-I (IGF-I) modulate the expression of L-type amino acid transporters in the muscles of spontaneous dwarf rats and L6 and C2C12 myocytes. Growth Hormone & IGF Research. 2018;42:66-73.
21. Spadaro O, Goldberg EL, Camell CD, Youm Y-H, Kopchick JJ, Nguyen KY, et al. Growth hormone receptor deficiency protects against age-related NLRP3 inflammasome activation and immune senescence. Cell reports. 2016;14(7):1571-80.
22. Halmos T, Suba I. The physiological role of growth hormone and insulin-like growth factors. Orvosi hetilap. 2019;160(45):1774-83.
23. Podlutsky A, Valcarcel-Ares MN, Yancey K, Podlutskaya V, Nagykaldi E, Gautam T, et al. The GH/IGF-1 axis in a critical period early in life determines cellular DNA repair capacity by altering transcriptional regulation of DNA repair-related genes: implications for the developmental origins of cancer. Geroscience. 2017;39(2):147-60.
24. Dominick G, Bowman J, Li X, Miller RA, Garcia GG. mTOR regulates the expression of DNA damage response enzymes in long‐lived Snell dwarf, GHRKO, and PAPPA‐KO mice. Aging Cell. 2017;16(1):52-60.
25. Bartke A, Hascup E, Hascup K, Masternak MM. Growth Hormone and Aging: New Findings. The World Journal of Men's Health. 2021;39.
26. Edifizi D, Schumacher B. Omics approaches for identifying physiological adaptations to genome instability in aging. International journal of molecular sciences. 2017;18(11):2329.
27. Young J, Bell S, Qian Y, Hyman C, Berryman DE. Mouse models of growth hormone insensitivity. Reviews in Endocrine and Metabolic Disorders. 2021;22(1):17-29.
28. Poudel SB, Dixit M, Neginskaya M, Nagaraj K, Pavlov E, Werner H, et al. Effects of GH/IGF on the Aging Mitochondria. Cells. 2020;9(6):1384.
29. Zhang F, Icyuz M, Liu Z, Fitch M, Sun LY. Insulin sensitivity in long-lived growth hormone-releasing hormone knockout mice. Aging (Albany NY). 2020;12(18):18033.
30. Di Pasquale C, Gentilin E, Falletta S, Bellio M, Buratto M, Degli Uberti E, et al. PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line. Endocrine. 2018;60(2):308-16.
31. Bartke A. Somatic growth, aging, and longevity. NPJ aging and mechanisms of disease. 2017;3(1):1-6.
32. Ciresi A, Amato MC, Pizzolanti G, Giordano Galluzzo C. Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. The Journal of Clinical Endocrinology & Metabolism. 2012;97(8):2907-15.
33. Lewitt MS. The role of the growth hormone/insulin-like growth factor system in visceral adiposity. Biochemistry insights. 2017;10:1178626417703995.
34. Colon G, Saccon T, Schneider A, Cavalcante MB, Huffman DM, Berryman D, et al. The enigmatic role of growth hormone in age-related diseases, cognition, and longevity. Geroscience. 2019;41(6):759-74.
35. Ben-Avraham D, Govindaraju DR, Budagov T, Fradin D, Durda P, Liu B, et al. The GH receptor exon 3 deletion is a marker of male-specific exceptional longevity associated with increased GH sensitivity and taller stature. Science advances. 2017;3(6):e1602025.
36. Werner H, Sarfstein R, Nagaraj K, Laron Z. Laron syndrome research paves the way for new insights in oncological investigation. Cells. 2020;9(11):2446.
37. Laron Z, Kauli R, Lapkina L, Werner H. IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome. Mutation Research/Reviews in Mutation Research. 2017;772:123-33.
38. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng C-W, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Science translational medicine. 2011;3(70):70ra13-70ra13.
39. Hannah-Shmouni F, Trivellin G, Stratakis CA. Genetics of gigantism and acromegaly. Growth Hormone & IGF Research. 2016;30:37-41.
40. Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly. Nature Reviews Disease Primers. 2019;5(1):1-17.
41. Bartke A. Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice. Neuroendocrinology. 2003;78(4):210-6.
42. Murtaza G, Khan AK, Rashid R, Muneer S, Hasan SMF, Chen J. FOXO transcriptional factors and long-term living. Oxidative medicine and cellular longevity. 2017;2017.
43. Kim S-E, Mori R, Shimokawa I. Does Calorie Restriction Modulate Inflammaging via FoxO Transcription Factors? Nutrients. 2020;12(7):1959.
44. Tanisawa K, Hirose N, Arai Y, Shimokata H, Yamada Y, Kawai H, et al. Inverse association between height-increasing alleles and extreme longevity in Japanese women. The Journals of Gerontology: Series A. 2018;73(5):588-95.
45. Laron Z. The GH-IGF1 axis and longevity. The paradigm of IGF1 deficiency. Hormones. 2008;7(1):24-7.
46. Nashiro K, Guevara-Aguirre J, Braskie MN, Hafzalla GW, Velasco R, Balasubramanian P, et al. Brain structure and function associated with younger adults in growth hormone receptor-deficient humans. Journal of Neuroscience. 2017;37(7):1696-707.
47. Guevara-Aguirre J, Rosenbloom AL, Balasubramanian P, Teran E, Guevara-Aguirre M, Guevara C, et al. GH receptor deficiency in Ecuadorian adults is associated with obesity and enhanced insulin sensitivity. The Journal of Clinical Endocrinology & Metabolism. 2015;100(7):2589-96.
48. Aguiar-Oliveira MH, Souza AHO, Oliveira CRP, Campos VC, Oliveira-Neto LA, Salvatori R. The multiple facets of GHRH/GH/IGF-I axis: lessons from lifetime, untreated, isolated GH deficiency due to a GHRH receptor gene mutation. European journal of endocrinology. 2017;177(2):R85-R97.
49. Wang T, Tsui B, Kreisberg JF, Robertson NA, Gross AM, Yu MK, et al. Epigenetic aging signatures in mice livers are slowed by dwarfism, calorie restriction and rapamycin treatment. Genome biology. 2017;18(1):1-11.
50. Garcia JM, Merriam GR, Kargi AY. Growth hormone in aging. Endotext [Internet]. 2019.
51. List EO, Basu R, Duran-Ortiz S, Krejsa J, Jensen EA. Mouse models of growth hormone deficiency. Reviews in Endocrine and Metabolic Disorders. 2021;22(1):3-16.

 ©IJSRED: All Rights are Reserved